{"id":"argx-213","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reaction"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARGX-213 is a monoclonal antibody that targets CD20, a protein expressed on the surface of B cells. By binding to CD20, ARGX-213 induces B cell depletion, which can be beneficial in the treatment of certain autoimmune diseases.","oneSentence":"Monoclonal antibody targeting CD20","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:54:20.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"}]},"trialDetails":[{"nctId":"NCT06968338","phase":"PHASE1","title":"A Study to Assess the Safety of ARGX-213 in Healthy Volunteers","status":"RECRUITING","sponsor":"argenx","startDate":"2025-04-11","conditions":"Healthy Volunteers","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARGX-213","genericName":"ARGX-213","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"Monoclonal antibody targeting CD20 Used for Chronic inflammatory demyelinating polyneuropathy (CIDP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}